Cytotoxic treatment of cancer is strenuous for the patient. Besides the worries that always come with a cancer diagnosis the cytotoxic treatment is a major strain on the body. Often patients loose their hair as a consequence of the treatment and many perceive this as a great additional burden. The biotech company Dignitana AB in Lund, Sweden offers a system that cools down the patient's scalp and thereby prevents hair loss. The system has existed on the market for several years. In cooperation with Kitron the next generation of the system shall now be developed.
The cooperation means that Kitron ASA's Swedish subsidiary Kitron AB shall develop a new complete product including hardware, software, mechanics and industrial design according to Dignitana's specifications. Kitron also expects to industrialise and manufacture the equipment for Dignitana. The assignment amounts to about SEK 5 million for Kitron. The project will of course comply with the prevailing medical technology standards in Europe and the USA.
"We will continue to improve our DigniCap system and at the same time make it possible to charge per treatment. The new system will be launched internationally and the cooperation with Kitron will facilitate the approval process in the USA" says Martin Waleij, managing director in Dignitana.
"The order is significant and an inspiring challenge" says Johan Sandstedt, Business Development Manager for medical technology in Kitron AB. "We will develop a product that is technically and functionally a market leader in the segment, has an ergonomic and aesthetic design and may also be manufactured at a lower cost than the current model".
11 January 2008
Kitron ASA
For further information, please contact:
Johan Sandstedt, Business Development Manager for medical technology in Kitron AB,
phone: (+46) 736 68 33 21, or e-mail:
johan.sandstedt@kitron.com
Kitron is one of Scandinavia's leading companies in development, industrialisation and production of electronics for the data/telecom, defence/marine, medical, automotive and other industries. The company is located in Norway, Sweden and Lithuania. Kitron had a revenue of about NOK 1.7 billion in 2006 and has about 1,300 employees. See also www.kitron.com.
Dignitana AB is an innovative biotech company that has developed an advanced system, DigniCap, to counteract hair loss during cytotoxic treatment. The effectiveness, patient friendliness and ease of use of the DigniCap system makes it unbeatable.